LISTED Australian medical life sciences company, Medlab Clinical has announced further strong data resulting from both clinical trial and approved Special Access Scheme (SAS) use of its nano-delivery form of cannabis, NanaBis.
Head to head comparisons between Nanabis and an ARTG-listed cannabis-based drug demonstrated a similar plasma level of THC and CBD, while NanaBis is only half the dose.
In addition, the rate of absorption for NanaBis was faster.
Medlab CEO, Dr Sean Hall this week presented a clinical update to medical practitioners as part of an on-going medical education program around NanaBis, saying the data was "very encouraging".
Hall said the trials were indicating NanaBis was safe and tolerable, with results repeatable.
Several case studies for NanaBis use under the Special Access Scheme in patients with severe pain were also discussed, with Hall citing ""significant improvements in quality of life inclusive of sleep and movement with reduced pain/restriction".
Other reported outcomes related to the reduction/replacement of previously prescribed medication (in particular opioids), reduction in pain severity scores and reduction of symptoms.
Hall said based on the trial activity, Medlab was actively pursuing regulatory pathways for the TGA in Australia, FDA in the USA and the European Medicines Agency, adding that "Medlab has a planned framework that should take NanaBis to an approved drug".
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Mar 19
